Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
暂无分享，去创建一个
A. Tefferi | W. Hogan | A. Pardanani | M. Elliott | M. Shah | K. Begna | J. Foran | C. Hanson | A. Al-Kali | N. Gangat | A. Mangaonkar | M. Litzow | H. Alkhateeb | J. Palmer | Kristen B. McCullough | T. Badar | M. Patnaik | Rimal Ilyas